E
Exciva
Targeted drug rescue for Alzheimer’s agitation and neuropsychiatry
About Exciva
Exciva is a Heidelberg biopharmaceutical company founded in 2016 that develops therapies for neuropsychiatric conditions using a “Targeted Drug Rescue” approach that repurposes and combines clinically validated compounds. Lead candidate Deraphan (including EXV-802) combines two clinically validated components, one a new chemical entity, for agitation associated with Alzheimer’s disease; after a successful Phase I safety study it is advancing into a multi-centre Phase II trial across Europe, the US and Canada. Leadership includes CEO François Conquet with co-founders Hans Moebius, Anton Bespalov and Sreenivasarao Vepachedu. After a €9 million Series A in 2021 (Andera Partners, LBBW Venture, Cure8), Exciva in January 2026 raised a €51 million ($59 million) Series B co-led by Gimv and EQT Life Sciences, with Fountain Healthcare Partners, LifeArc, Modi VC, Carma Fund and Andera Partners returning, to fund Phase II development. Sources: Gimv / EQT 20 Jan 2026.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Heidelberg, Germany
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 74.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Alzheimers Disease, Precision Medicine, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
Knowledge graph
News
More headlines
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2026 | $56M | $224M | Fountain Healthcare Partners · LifeArc Ventures · Andera Partners · Modi Venture Partners | ↗ |
| SERIES AOther financing | Oct 2021 | $9.9M | $40M | Cure8 Ventures · Andera Partners · LBBW Venture Capital | ↗ |
Growth signals
Latest recorded traffic for Exciva is 260 monthly website visits, down 64.4% over the last three months. Exciva's team grew 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 iLoFAI and photonics platform for personalized drug discovery. |
London, United Kingdom | Operational | 40 | $13M | $22M |
 ADmit TherapeuticsEpigenetic blood test for early Alzheimer's prognosis |
Esplugues de Llobregat, Spain | Operational | |||
 Loto BiotechProprietary platform developing siRNA therapies for rare diseases |
L'Aquila, Italy | Operational | |||
 TheremiaLeverage AI for inclusive healthcare |
Paris, France | Operational | |||
 Kairos Discovery developing innovative targeted therapies in oncology |
Lyon, France | Operational | |||
 RaidiumRaidium foundation model: Radiology augmented GPT to tackle the complexity of precision medicine |
Roubaix, France | Operational | |||
 Shenzhen Huixin Biomedical TechnologyDeveloping automated exosome purification systems for early cancer diagnosis and treatment applications |
Ningbo, China | Operational | |||
 Stipple BioUnlocking cellular profiling and target discovery with epitope resolution |
Cambridge, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Exciva in the Heidelberg ecosystem
The Exciva office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Andera Partners- CVCure8 Ventures
LBBW Venture Capital
Gimv
EQT Life Sciences
Fountain Healthcare Partners
LifeArc Ventures
Modi Venture Partners
CARMA FUND Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Exciva on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Exciva’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.